Trial reportClinical journal of the American Society of Nephrology : CJASN2017
Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Interventions for preventing haemodialysis dysequilibrium syndrome.The Cochrane database of systematic reviews · 2024Pooled it
- Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026Review
- Calcimimetics and CaSR signaling in CKD-MBD: bone-immune-vascular crosstalk and therapeutic potential.Frontiers in immunology · 2026Review
- Calcimimetic Prescriptions in Fee-for-Service Medicare Beneficiaries Undergoing Dialysis.JAMA health forum · 2025Article
- Research progress on cellular behavior of CaSR in cardiovascular diseases.Frontiers in immunology · 2025Review
- Glycolate oxidase-1 gene variants influence the risk of hyperoxaluria and renal stone development.World journal of urology · 2024Article
- Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.Current osteoporosis reports · 2023Review
- Haplotype of CaSR gene is associated with risk of renal stone disease in West Indian population.Urolithiasis · 2022Article
- Genetic Variants Associated With Mineral Metabolism Traits in Chronic Kidney Disease.The Journal of clinical endocrinology and metabolism · 2022Article
- Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Evaluation of the Interaction of Cinacalcet with Calf Thymus dsDNA: Use of Electrochemical, Spectrofluorimetric, and Molecular Docking Methods.Biosensors · 2022Article
- APOL1 G3 Variant Is Associated with Cardiovascular Mortality and Sudden Cardiac Death in Patients Receiving Maintenance Hemodialysis of European Ancestry.Cardiorenal medicine · 2022Article
- The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.Scientific reports · 2021Article
- The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis.Cardiorenal medicine · 2021Article
- Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.American journal of nephrology · 2019Article
- Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease.Seminars in nephrology · 2018Review
- Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.Seminars in nephrology · 2018Review
- Rationale to reduce calcium intake in adult patients with chronic kidney disease.Current opinion in nephrology and hypertension · 2018Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesWe tested the hypothesis that single nucleotide polymorphisms (SNPs) in the calcium-sensing receptor ( DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed DNA samples in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial, a randomized trial comparing cinacalcet to placebo on a background of usual care. Of the 3883 patients randomized, 1919 (49%) consented to DNA collection, and samples from 1852 participants were genotyped for 18
resultsThere were modest associations of
conclusionsThese modest associations, if validated, may provide explanations for differences in CKD-mineral bone disorder observed in EA and AfAn populations, and for differential biochemical responses to calcimimetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.